Community-Based Seroprevelance of SARS-CoV-2 in Saudi Arabia
Open Access
- 10 December 2022
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32419
Abstract
The new coronavirus disease 2019 (COVID-19) is a major global concern. Due to the number of asymptomatic cases that go untested, the actual proportion of those who have been infected is likely to be higher than the reported prevalence. Thus, investigating the exact proportion of those who developed antibodies against the virus through serological surveys is crucial to identify the immune status of the population and direct public health decisions accordingly. The aim of this study is to estimate the seroprevalence of SARS-CoV-2 in the community and to describe the epidemiological characteristics of the discovered cases. Between July and October 2020, a cross-sectional sero-survey was conducted including a total of 15,873 serum samples collected from seven regions within the kingdom. Using a multistage convenient sampling, people were invited to participate in an interviewer-administrated questionnaire. Afterward, blood samples were collected and seroprevalence was determined using the SARS-CoV-2 virus IgG/IgM antibody detection kits (ELISA). A p-value of <0.05 and 95% CI were used to report the significance. The overall seroprevalence of SARS-CoV-2 in the sample was 17.0%, and Makkah region constituted the highest number of reactive cases (33.3%). There was a significant association between all comorbidities and having symptoms except for diabetes. In addition, age, education, nationality, and region were all significant predeterminants of sero-result. Also, contact with a confirmed or suspected case increased the risk of being seropositive by nearly 1.5 times. This study estimated the national seroprevalence of SARS-CoV-2 in Saudi Arabia to be 17%. At the time of this study, most of the population did not have the SARS-CoV-2 specific antibodies. This suggests that the population is still below the threshold of herd immunity and emphasizes the importance of mass vaccination programs and abiding by recommended prevention precautions.Keywords
This publication has 23 references indexed in Scilit:
- Kinetics of viral load and antibody response in relation to COVID-19 severityJournal of Clinical Investigation, 2020
- Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological studyThe Lancet, 2020
- Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based studyThe Lancet, 2020
- Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteasesInfection, 2020
- Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)Clinical Infectious Diseases, 2020
- Comorbidity and its Impact on Patients with COVID-19SN Comprehensive Clinical Medicine, 2020
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infectionsNature Medicine, 2020
- Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020JAMA, 2020
- Real-time RT-PCR in COVID-19 detection: issues affecting the resultsExpert Review of Molecular Diagnostics, 2020
- Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, KoreaJournal of Korean Medical Science, 2020